Anti-VEGF injections were independently associated with a higher likelihood of developing any systemic AE (OR 1.8, 95% CI 1.7-1.9) after controlling for a number of factors including age, sex ...

Greater vision improvements were seen in people with macular edema secondary to retinal vein occlusion who received more anti-VEGF injections over the course of 5 years.

Adherence to intravitreal anti-VEGF injections may be challenging for some patients with neovascular age-related macular degeneration, putting them at risk for poor vision outcomes, according to ...

When administering anti-VEGF treatments to patients with wet age-related macular degeneration, diabetic macular edema or retinal vein occlusion who have severe glaucoma, be mindful of the speed ...

Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...

Anti-VEGF Injections Versus Surgery for Submacular Hemorrhage in Age-Related Macular Degeneration —A recent systematic review and meta-analysis comparing anti-VEGF and surgery for SMH found ...

4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...

Kidney failure in anti-VEGF treatments occurs at similar rates whether patients receive ranibizumab, bevacizumab, or aflibercept.

Adverum Biotechnologies presented 26-week interim data from the LUNA Phase 2 trial for Ixo-vec in wet AMD. The analysis showed significant reductions in anti-VEGF injections and positive visual ...

4DMT Molecular Therapeutics Inc. is looking ahead to phase III as positive data continue to roll out for gene therapy candidate 4D-150 in wet age-related macular degeneration (AMD), with the results ...